Key breakthrough in human cancer treatment! RedMed’s new therapy doubles survival time for “King of Cancers” patients and reduces risk of death by 60%.
```
A historic breakthrough has been achieved in the global field of pancreatic cancer treatment.
The innovative drug Daraxonrasib, developed by RedMed, has, in the latest phase 3 clinical trial, increased the survival time for patients with advanced pancreatic cancer to 13.2 months, nearly doubling the 6.7 months achieved